Boston, MA – Capstone Partners LLC, a leading national investment banking firm, announced that it has successfully advised J.H. Emerson Company (“Emerson” or the “Company”) on its recent acquisition by Respironics, Inc. The Company is involved primarily in the manufacture and distribution of the CoughAssist® device that Respironics had previously distributed. Capstone served as the exclusive investment banking advisor to Emerson during the transaction process.
J.H. Emerson Company, founded in 1928, designs and manufactures innovative and reliable medical devices. The CoughAssist® device, Emerson’s flagship product, provides secretion clearance to patients with Chronic Obstructive Pulmonary Disease as well as certain other respiratory ailments and conditions. CoughAssist® gives these patients an effortless way to remove respiratory secretions that could otherwise instigate an exacerbation of their illness.
Respironics, Inc. is a leading developer, manufacturer and distributor of innovative products and programs that serve the global sleep and respiratory markets. Focusing on emerging market needs, Respironics is committed to providing valued solutions to help improve outcomes for patients, clinicians and health care providers. Respironics markets its products in 131 countries and employs more than 4,900 associates worldwide.
